OXIGENE ANNOUNCES PRECLINICAL DATA FOR OXI4503

OXiGENE announced the presentation of positive, new preclinical data supporting the development of its clinical candidate, OXi4503.

Independent researchers presented results from ongoing studies that highlight the efficacy of OXi4503, a prodrug that can be activated to a novel ortho-quinone compound, for the treatment of cancer. The data were presented at the 9th International Workshop on the Tumor Microenvironment Meeting being held at Christ Church College in Oxford, UK.